TABLE 3.
PDC by Index DPP-4 in MAPD and Commercial Populations
| Sitagliptin | Saxagliptin | Linagliptin | |
|---|---|---|---|
| MAPD | n = 17,292 | n = 4,282 | n = 1,286 |
| Mean PDCa (SD) | 72.1 A (27.7) | 72.3 A (27.8) | 67.2 B (28.2) |
| Number adherent (PDC ≥ 80%) | 8,626 | 2,181 | 533 |
| (% adherent)b | (49.9) | (50.9) | (41.4) |
| Adjusted OR of adherence compared with linagliptin (95% CI)c | 1.40 (1.25-1.57) P < 0.001 |
1.46 (1.29-1.66) P < 0.001 |
Reference |
| Commercial | n = 2,368 | n = 643 | n = 218 |
| Mean PDCa (SD) | 73.6 (27.4) | 72.4 (25.9) | 69.8 (26.4) |
| Number adherent (PDC ≥ 80%) | 1,278 | 326 | 96 |
| (% adherent)b | (53.0) | (51.0) | (44.0) |
| Adjusted OR of adherence compared with linagliptin (95% CI)c | 1.47 (1.11-1.95) P = 0.006 |
1.326 (0.97-1.81) P = 0.419 |
Reference |
aANOVA mean values followed by different letters (A, B) are significantly different (P < 0.001 MAPD; P = 0.09 commercial); GLM controlling for age, gender, DCSI, and pre-index insulin use, also significant for MAPD and not significant for commercial (P = 0.069 sitagliptin vs. linagliptin, P = 0.240 saxagliptin vs. linagliptin).
bChi square: P < 0.001 MAPD; P = 0.012 commercial.
cLogistic regression controlling for age, gender, DCSI, and pre-insulin use.
ANOVA = analysis of variance; CI = confidence interval; DCSI = Diabetes Complications Severity Index; GLM = general linear modeling; MAPD = Medicare Advantage Prescription Drug; OR = odds ratio; PDC = proportion of days covered; SD = standard deviation.